Scenic Enters License and Research Agreement with Alnylam

Core Insights - Scenic Biotech has entered a license and research agreement with Alnylam Pharmaceuticals to utilize its Cell-Seq platform for discovering new targets for RNAi therapeutics [1] - This collaboration is a significant validation of Scenic's Cell-Seq platform, which connects cellular pathways to actionable drug targets, and is part of Scenic's strategy to advance its pipeline of first-in-class disease-modifying therapies [2] - Scenic Biotech's Cell-Seq platform has previously facilitated collaborations with major biotech companies like Genentech and Bristol Myers Squibb, focusing on genetic insights for novel therapeutic discovery [2] Company Overview - Scenic Biotech is pioneering modifier therapy, which aims to treat genetic disorders by targeting genes that can improve or bypass the effects of disease rather than the primary mutation [3] - The company has a robust pipeline of small molecule programs derived from its proprietary Cell-Seq platform and engages in strategic collaborations with multinational pharmaceutical leaders [3] - By unlocking new pathways in the genome, Scenic Biotech is developing a range of modifier therapies aimed at helping patients with severe diseases [3]